PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
Feature|Videos|June 5, 2025
Training Centers and eCommerce: A Look Into Federal Equipment Company’s Pharma Innovations
How Techceuticals, PharmParts, and smart auction strategies are ushering in a new era of efficiency and innovation for CDMOs
Adam Covitt, President of Federal Equipment Company, shares exciting updates from Techceuticals—the company’s state-of-the-art training center in Cleveland, Ohio—where new technologies are enhancing hands-on learning and client engagement. He also discusses PharmParts, a streamlined eCommerce platform designed to help CDMOs quickly source critical spare parts with next-day delivery. Learn more about:
- Techceuticals and PharmParts, value-add businesses that focus on novel technologies, comprehensive training, and simplicity for CDMOs.
- How the trade tariffs are fueling the shift back to oral solid dosage (OSD) products like tablets and capsules.
- How online industrial auctions are giving pharma manufacturers a smarter way to monetize surplus equipment and reinvest in future-ready technologies.
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Trending on Pharmaceutical Technology
1
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
2
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
3
PharmTech AI Pulse Check: Availability Bias Threatens AI Regulatory Reviews
4
What the Olanzapine Depot Approval Means for CMC Teams
5